Keros Therapeutics, Inc.
KROS
$14.91
$0.151.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 232.84M | 214.71M | 3.55M | 651.00K | 271.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 232.84M | 214.71M | 3.55M | 651.00K | 271.00K |
| Cost of Revenue | 13.44M | 10.45M | 0.00 | 30.23M | 15.15M |
| Gross Profit | 219.41M | 204.26M | 3.55M | -29.58M | -14.88M |
| SG&A Expenses | 45.46M | 40.94M | 40.75M | 39.19M | 38.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 232.53M | 225.02M | 214.38M | 204.69M | 188.93M |
| Operating Income | 312.00K | -10.31M | -210.83M | -204.03M | -188.66M |
| Income Before Tax | 26.89M | 14.56M | -187.05M | -181.57M | -168.05M |
| Income Tax Expenses | 8.12M | 10.34M | 300.00K | -- | -- |
| Earnings from Continuing Operations | 18.77 | 4.21 | -187.35 | -181.57 | -168.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.77M | 4.21M | -187.35M | -181.57M | -168.05M |
| EBIT | 312.00K | -10.31M | -210.83M | -204.03M | -188.66M |
| EBITDA | 1.67M | -9.01M | -209.60M | -202.89M | -187.62M |
| EPS Basic | 0.35 | -0.14 | -5.01 | -5.21 | -5.13 |
| Normalized Basic EPS | 0.35 | 0.07 | -3.13 | -3.25 | -3.20 |
| EPS Diluted | -1.10 | -1.59 | -6.42 | -6.62 | -6.46 |
| Normalized Diluted EPS | 0.32 | 0.04 | -3.13 | -3.25 | -3.20 |
| Average Basic Shares Outstanding | 159.10M | 154.59M | 149.72M | 139.51M | 131.58M |
| Average Diluted Shares Outstanding | 159.56M | 155.05M | 149.72M | 139.51M | 131.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |